M
yocardial infarction (MI) and ischemic stroke (IS) are both rare conditions in adolescence with different risk factors, presentation, and prognosis from those in the adult. 1, 2 Premature arterial events in the young are frequently associated with the presence of congenital vascular anomalies, cardiac malformations, presence of severe inherited atherosclerotic risk factors, infective or autoimmune inflammatory diseases, and rheological disorders, whereas traditional atherosclerotic risk factors (hypertension, dyslipidemia, diabetes mellitus, obesity, and smoking) are uncommon. 2, 3 Antithrombin (AT)-in earlier times termed AT IIIis a major inhibitor of thrombin and activated factor X. 4 In the presence of heparin, the inhibition is approximately 1000-fold more effective. The prevalence of AT deficiency in the general population and in patients with venous thromboembolism (VTE) is estimated to range from 1:2000 to 1:3000 and from 1:20 to 1:200, respectively. Accordingly, patients with AT deficiency hold an approximately 25 to 50-fold relative risk for VTE. 5 In comparison, association of arterial thromboembolism with AT deficiency is extremely rare, thus no such epidemiological data is yet available. ). The pathologic role of AT deficiency in the development of VTE is well established. In contrast, as for arterial thromboembolism the association is still ambiguous. 6 Although reports on acute arterial events associated with AT deficiency are sparsely published, 7-9 a recent epidemiologic study supported the role for AT Cambridge II, an AT type II RS variant (p.Ala384Ser) in arterial thrombosis. 10 AT Basel described in 1986 is an AT type II HBS variant with normal RS but impaired heparin binding affinity as a result of the substitution of proline by leucine at position 41.
11
Lipoprotein(a) [Lp(a)], a cholesterol-rich plasma lipoprotein promotes both arteriosclerosis and thrombogenesis. High Lp(a) level is now considered as an independent risk factor for cardiovascular diseases (CVDs). 12 In a recent meta-analysis risk ratios for nonfatal MI and IS per 3.5-fold higher baseline Lp(a) level after adjustment for cardiovascular risk factors were 1.12 (95% confidence interval, 1.07-1.18) and 1.10 (95% confidence interval, 1.02-1.18), respectively. 13 This report supports pathophysiologic roles for AT Basel and elevated Lp(a) level in arterial thrombogenesis with a possible additional effect on the development of MI and IS in our adolescent patient.
CASE REPORT
A 15-year-old white boy was admitted to hospital complaining of sudden onset of chest pain after mild physical exercise. Diagnosed with incomplete atrioventricular septal defect in infancy he underwent surgical repair (atrial septal defect and cleft mitral valve closure) at the age of 13 years. Elevated cardiac troponin I and total and cardiac specific creatine kinase levels suggested myocardial damage localized to the anterior wall of the left ventricle by echocardiography scan and 12-lead ECG (Fig. 1) . Coronary angiogram indicated overall angiographically normal coronary arteries and revealed a sole thrombotic occlusion of the left anterior descending coronary artery. The vessel was successfully recanalized by intracoronary stent implantation (Fig. 2) . Moderate leukocytosis on admission was caused by elevated absolute neutrophil count; however, neither clinical symptoms nor further laboratory investigations were indicative of inflammatory process.
Twenty months later, the patient suffered IS associated with left-sided hemiparesis despite continuously having been on effective antiplatelet therapy confirmed by PFA-100 Closure Time Determination, Platelet Aggregation, and Secretion Studies and investigation of vasodilator-stimulated phosphoprotein phosphorylation by flow cytometry (Coll/EPI closure time: >300 s-reference range: 63 to142 s; ADP aggregation-5 mM, 20 mM, and 40 mM in the presence of PGE1: significantly decreased, single-phase aggregation, no ATP secretion; platelet reactivity index: 39.8%-control: 77.3%, respectively). Computed tomography angiography showed partial occlusion at the bifurcation of the right middle cerebral artery. Successful systemic thrombolysis allowed full neurological recovery; however, ischemic cerebral lesion remained (Fig. 3 ). Transthoracic and transesophageal echocardiography scans conducted by an experienced examiner could not detect any cardiac source for arterial embolism. Receiving combined antiplatelet and oral anticoagulation therapy the patient remains free of symptoms to this day.
Cardiovascular risk factors and family history for CVDs were thoroughly investigated after the MI ( Table 1 ). The majority of the laboratory test values were within their reference range with the exception of an elevated Lp(a) level. Furthermore, AT activity was decreased, whereas the AT antigen level was normal suggesting a type II AT deficiency. To reveal a possible genetic background for decreased AT activity direct DNA sequencing of the coding regions including exon-intron boundaries and promoter region of the AT gene was performed. A cytosine to thymine nucleotide base change 
DISCUSSION
Imaging techniques demonstrated intra-arterial thrombi and normal vascular anatomy with no signs of undue atherosclerosis or inflammatory disease in both the coronary and the cerebral arteries. Hence, a hypercoagulable state rather than structural damage or vasoactive mechanism could be suggested for the cause of the recurrent arterial occlusion.
Hemostasis laboratory investigations excluded the presence of most common hypercoagulable conditions, but revealed type II AT deficiency caused by a single amino acid exchange (p.Pro41Leu, AT Basel) in the N-terminal region of the protein. This mutation leads to impaired heparin cofactor activity of AT-a type II HBS variant.
11
Most of the mutations modifying the heparin binding affinity of AT published so far are located in the N-terminal region of the molecule and are generally associated with lower thrombosis risk compared with other types of AT deficiency.
14 Although most of the patients with such mutations suffered from venous thrombosis severe arterial thrombosis was also described in the case of homozygous HBS mutation. 15 According to our knowledge, this is the first case to report AT Basel associated with arterial thrombosis.
Lp(a) consists of a cholesterol-rich LDL
AQ3
-like particle and a plasminogen-like glycoprotein, apolipoprotein(a). Although the physiological function of Lp(a) is still unclear in consequence of its dual structure, Lp(a) is implicated in the process of both atherosclerosis (eg, by promoting plaque inflammation and increasing vascular smooth muscle cell proliferation) and thrombosis (by a combined prothrombotic and antifibrinolytic effect). 16 It is to note, however, that despite its presumptive association with arterial thromboembolism the role of Lp(a) in the development of venous thromboembolic events is still controversial. 17, 18 On the basis of recent meta-analyses high Lp(a) plasma level is now considered to be an independent cardiovascular risk factor, that is, Lp(a)-associated risk does not depend on increased non-HDL AQ4 cholesterol concentrations nor on the levels or presence of other risk factors.
12 Increased Lp(a) level is determined mainly genetically, thus its robust and specific association with CVD in adults presumes that Lp(a) is also causally related to CVD in the young. 19 The implication of Lp(a) in both premature MI and childhood IS is therefore suggested. 2, 20 In the case of AT deficiencies, similarly to other thrombophilias, a decision on long-term therapy should be made knowing the circumstances of the thrombotic event and weighing up all the patient's risk factors for recurrence. After VTE, long-term vitamin K antagonist therapy should be initiated. Nevertheless, long-term antithrombotic treatment after an arterial thrombotic event is less definite. In the presence of overt arteriosclerosis or its risk factors, antiplatelet therapy is thought to be sufficient. In contrast, if AT deficiency is deemed to be one of the main reasons for the thrombotic event long-term anticoagulation, an approach based on theoretical considerations rather than solid evidence, may be appropriate. 4 The failure of lone antiplatelet therapy to prevent a second arterial thrombosis in our young patient with an AT type II HBS variant supports this assumption.
Elevated Lp(a) as an independent genetic risk factor should be considered in the clinical management of intermediate or high-risk cardiovascular patients. The scope of therapeutic interventions available for lowering Lp(a) 16 Yet, in case of intermediate or high absolute risk for CVD, therapeutic recommendation suggests lowering of Lp(a) to a desirable level below the 80th percentile (<500 mg/L). 19 Hence, in patients with premature or recurrent CVD and increased Lp(a) level, in addition to the effective cholesterol reduction with a statin, the introduction of niacin in the therapy may be justified.
Reports on the association of AT type II HBS mutations with arterial thrombosis are rare. Here, the presumably additional effect of the high Lp(a) level on the prothrombotic condition caused by impaired AT activity could have contributed to the development of recurrent arterial thrombosis. We conclude that in young patients presenting with arterial thrombotic event but no predisposing medical history or conspicuous risk factors prudent investigation for special conditions such as thrombophilia or recently established cardiovascular risk factors-for example, Lp(a)-should be conducted. In addition, if an AT type II HBS variant is identified in the background of the thrombotic event introduction of oral anticoagulant therapy is recommended regardless of its arterial or venous nature.
